Tokyo-based Astellas Pharma (TYO: 4503) has been awarded EU approval for its neurogenic detrusor overactivity (NDO) therapy solifenacin succinate in oral suspension form. The drug is indicated for children aged 2 to 18 years. NDO is a bladder dysfunction in which increased storage pressure can put the upper urinary tract at risk of deterioration. Commonly observed in patients with conditions such as multiple sclerosis and spinal cord injury, it causes urinary incontinence in approximately 50% of MS patients. Read more.
Source: The Pharma Letter, March 9, 2018